Management Forum Logo

Presented by
Management Forum

Drug Discovery: A Step-by-Step Introduction Training Course

The course takes you on a science-based drug discovery journey. You will travel from inception of a new project to the point of hand-over of the newly discovered molecule to the Development Team for pre-clinical and clinical studies. The course breaks down the long, multi-faceted discovery process into individual steps which build towards this key goal. The focus is on how essential science, technology and infrastructure elements are constituted, deployed and integrated to maximise the likelihood of a successful discovery project.

26-27 Jan 2023
+ 2 more dates

Need help?  Enrol or reserve

  • Format: Live online, Classroom
  • CPD: 12 hours for your records
  • Certificate of completion

Overview

Drug discovery is a compelling mixture of established science and new, cutting-edge developments. It is powered by the know-how of its stakeholders and a long history which provide us with guidance on the scientific path for a successful project. The disciplines required include Biology, Biochemistry, Molecular Biology, Medicinal Chemistry and Informatics (and their sub-disciplines) with the support of major infrastructure and extensive non-scientific functions (Management, Financial, Commercial, Legal etc). All involved must work in harmony over a long timescale to successfully reach the final goal. This course has been designed to steer you through the process and focuses on small molecule drug discovery, making some reference to biologics.

Each company carries out drug discovery in a unique manner and the process continually evolves; however, there is a ‘Classical Model’ that is often followed and will be presented here. The programme describes how the project begins by selecting the disease to be treated, and then identifying a protein target whose modulation by a compound or biologic will have the required therapeutic effect based on the molecular mechanism of the disease.  A large number of compounds or biologics are then generated and iteratively optimised for a wide range of key chemical, physical and biological attributes based on past experience.  A lead (or lead series) of compounds is eventually selected which is further optimised to generate the clinical candidate. The science base and phasing of these activities will be covered together with the realities of the Pharma - Biotech environment in which they occur.

This is an excellent opportunity to engage with the drug discovery process and the elements involved with an expert in this field. The course will include a number of interactive exercises to aid the learning experience.

Benefits of Attending

Gain an understanding of the:

  • most frequently employed scientific approaches
  • key stages of drug discovery, their timelines and ordering
  • major science and technology platforms and infrastructure requirements
  • terminology commonly used by the drug discovery industry
  • scientific, commercial and financial landscape shaping drug discovery

Who Should Attend

  • Those who have recently transitioned into Pharma-Biotech from, for example, Academia and wish to get a global view of Drug Discovery.
  • Those already established within Pharma-Biotech in a specialist role who wish to see the bigger picture. 
  • Those within companies providing services or collaboration with Pharma-Biotech who want to gain a better understanding of their customer or collaborator.
  • Typical attendees have a science-based background and are often:
    • Biologists, 
    • Molecular Biologists
    • Chemists
    • Information Scientists
    • Project Managers
    • General Managers
    • Commercial Managers
    • Patent Attorneys
    • Lawyers
    • Technology Transfer Managers

Enrol or reserve

The Drug Discovery: A Step-by-Step Introduction course will cover:

Welcome and Introduction

The Drug Discovery Landscape

Typical drug discovery considerations:

  • Essential elements
  • Typical Milestones, decision points and pipeline
  • Drug Discovery strategies
  • Drug Discovery costs and drug revenues
  • Reducing attrition
  • Nomenclature
  • Scientific skills base required (Medicinal Chemistry, Biology, Molecular Biology, ADMET/DMPK, Informatics/Artificial Intelligence)
  • Small Molecules v. Biologics as drugs

Project Initiation

Best practice:

  • Generating a TPP (Target Product Profile)
  •  Selecting a viable Project

Target Protein Selection

How to select the right protein drug target for the disease:

  • Target Validation/Hypothesis generation
  • Genomics and Proteomics in Target selection
  •  Drug action at the cellular level

Target Protein Selection (continued)

  • Target tractability.
  • Major classes of Target proteins for existing small molecule drugs:
    • G-Protein-Coupled Receptors, Ion Channels, Nuclear Receptors, Kinases 

Lead / Lead Series Identification

The path to obtaining a lead or lead series with the quality attributes to become a clinical candidate. An outline of the key scientific tools of drug discovery:

  • Bioactivity assays of compounds, Low/Medium throughput screening, Bioactivity assay formats, Transformed cells, Stem cells, Organoids
  • Potency quantification - key constants and parameters
  • Targeted Protein Degradation
  • Selectivity Analysis
  •  Biostructural Analysis of the compound–protein target structure (X-Ray diffraction, Cryo-electron Microscopy, Google AlphaFold).
  • E-Docking

Recap of Day One

Lead / Lead Series Identification (continued)

  •  High Throughput Screening (HTS)
  •  Company compound library
  • Virtual company compound library and its e-screening

In vitro ADMET methodologies and their application:

  • Compound absorption at the gut and blood-brain barrier, bioavailability
  •  Drug Metabolism: Cyp 450 / drug-drug interactions / Glucuronidation / P-glycoprotein / Metabolic stability measurement/ The Prodrug Strategy  
  • Protein binding of compounds

Lead / Lead Series Identification (continued)

Medicinal chemistry:

  • Multidimensional Optimisation (MDO) of compounds
  • Compound Synthesis and automation
  • Chemical and physical properties of drug-like compounds
  • Drug-Protein Target bonding chemistry
  • Drug design physical/chemical parameters (e.g. Lipinski/Schultz ‘rules’)

Lead / Lead Series Identification (continued)

  • Animal model studies
  • Efficacy in animal models of disease, examples:
    • Inflammation
    • Cancer
    • HIV-AIDS
    • Essential attributes of a Lead Compound
    • Phasing of Scientific activities in Lead Identification for small molecules

Clinical Candidate Identification

Final ‘polishing’ of the lead with a view to its nomination to enter Pre-clinical and Preclinical Development:

  • Essential attributes of a clinical candidate
  •  Manufacture
  • Formulation
  • Pharmacokinetics (PK) and Pharmacodynamics (PD)

Clinical Candidate Identification (continued)

  • Toxicology and Toxicology Assays in vitro and in vivo / hERG.
  • Allometric Scaling.
  • Entry into Human Enabling Development stage.

Q & A

The course will include a number of interactive exercises throughout the two days

Enrol or reserve

Peter A. Lowe
NovoBio

After a Ph.D and postdoctoral positions in the UK and USA in protein biochemistry Peter joined Celltech (now part of UCB Pharma). There he was involved in biologics discovery. His next relevant position was with Roche where he became a senior manager in Biological Technology discovering small molecule antiviral drugs against HIV, Flu and Hepatitis C. Peter then went on to leadership positions in small/mid-sized Biotech companies in the UK and Switzerland before starting a Pharma-Biotech consultancy based near Cambridge, UK.

More details

Book Drug Discovery: A Step-by-Step Introduction Live online/Classroom training

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

26-27 Jan 2023

Live online

09:30-17:00 UK (London) (UTC+00)
10:30-18:00 Paris (UTC+01)
04:30-12:00 New York (UTC-05)
Course code 12859

  • GBP 1,099 1,299
  • EUR 1,579 1,859
  • USD 1,786 2,098

Until 22 Dec

View basket 

 
Not ready to book yet?

for 7 days, no obligation

11-12 May 2023

Classroom
Rembrandt Hotel
London

09:00-17:00 UK (London)
Course code 12852

  • GBP 1,299 1,499
  • EUR 1,819 2,099
  • USD 2,026 2,338

Until 06 Apr

  • 2 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

 
Not ready to book yet?

for 7 days, no obligation

21-22 Sep 2023

Live online

09:30-17:00 UK (London) (UTC+01)
10:30-18:00 Paris (UTC+02)
04:30-12:00 New York (UTC-04)
Course code 12853

  • GBP 1,099 1,299
  • EUR 1,579 1,859
  • USD 1,786 2,098

Until 17 Aug

View basket 

 
Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price.

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

Yesim NURKO
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy